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Abstract
The field of stem cell research has been growing more because of the interest in
using stem cells to cure diseases and heal injuries. Human embryonic stem cells, because of
the controversy surrounding them—and subsequently the difficulties in acquiring samples
of the existing aging cell lines—can only be used in limited capacities. While the
development of induced pluripotent stem cells in the last decade has allowed the field to
progress closer to medical treatments, the low efficiency of reprogramming a somatic cell
to a pluripotent state, and the vast molecular and genomic differences between human
embryonic stem cells and human induced pluripotent stem cells is still an issue. Therefore,
the goal is to discover methods, chemicals, and factors that can reduce these differences
and increase the efficiency of inducing pluripotency.
This proposal aims to look at the effects of the protein ECAT1 in inducing
pluripotency in human somatic cells. Little is known about ECAT1, otherwise known as
Embryonic Stem Cell-Associated Transcript 1, beyond its presence in human embryonic
stem cells and oocytes and its absence in differentiated cells. While originally considered by
scientists during the development of the reprogramming technique, ECAT1's effects have
not been tested in humans. Therefore, a series of experiments will be performed in which
ECAT1 will be used in conjunction with OSKM to induce pluripotency in adult human dermal
fibroblasts, which will then be differentiated into spinal motor neurons. The three stages of
this proposal--inducing pluripotency, comparing pluripotencies in the reprogrammed cells
and embryonic stem cells, and differentiating the stem cells--should answer questions
about ECAT1 and the reprogramming process. It is predicted that ECAT1 should reduce the
genomic and molecular differences between embryonic stem cells and induced pluripotent
stem cells. ECAT1's presence should also increase the efficiency of reprogramming as well as
successful differentiation to other cell types.
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Introduction
The search for cures to diseases such as cancer, Parkinson’s, sickle cell anemia, and
diabetes has been long and difficult. Similarly, a search for solutions to spinal cord injury
and other debilitating injuries has proven slow and relied on mechanical technology. The
use of stem cells as a solution has been gaining popularity since their discovery.

The Discovery of the Stem Cell
The discovery of the stem cell arose through observations of anomalous
teratocarcinomas. Scientists discovered that tumor cells have origins in embryonic cells, and
that cells taken from a tumor, when injected elsewhere, could produce a variety of different
cell-types.1-3 These cells were termed to be stem cells, and research progressed to using cell
feeder layers to establish what are now known as embryonic carcinoma cells. Discoveries in
mice preceded discoveries of human embryonic stem cells, beginning with the search for a
cure for leukemia—the first experiment using stem cells was of bone marrow
transplantation in irradiated mice, which led to the formation of multilineage colonies and
to the idea that stem cells could be used as a medicinal technique.1,2
Scientists began work using hematopoietic stem cells—stem cells that give rise to all
cells of the blood system2—and continued to develop the extremely difficult bone marrow
transplant procedure using these cells. At the same time, research dealt with the properties
of non-hematopoietic stem cells, specifically focusing on whether carcinomas were the only
source.
To aid in this endeavor, the effort focused on enzymes and factors that
characterized stem cells. In the 1970’s, one such enzyme, alkaline phosphatase, was shown
6

to play a major role in maintaining the main characteristic of pluripotency—the ability of a
cell to differentiate into most cell types—in a stem cell. In particular, alkaline phosphatase
was instrumental in uncovering the identities of other pluripotency-related enzymes such as
SSEA-3, SSEA-4, and NANOG.4 The enzymes and markers were all responsible for the ability
of embryonic stem cells to be grown indefinitely in the pluripotent state under optimal
conditions, without differentiating.3
Then, in the 1980’s, the first noncarcinomal embryonic stem cells were established
from mice. This eventually led to the generation of ES cell lines from humans in the late
1990’s.1

Debating Embryonic Stem Cells
With the potential applications for human embryonic stem cells (hESCs) much
publicized, debate still swirled around the idea of harvesting cells from a human embryo.
Arguments over whether a human embryo was considered a human life and whether
harvesting an embryo’s cells was considered stealing murder led to the passing of legislation
in the United States. While experimentation on human embryos faced major barriers in
terms of federal funding—President Bill Clinton’s administration prohibited the use of funds
used in research that led to the destruction of an embryo regardless of its source—stem
cells faced no such restrictions.
In 2001, President George W. Bush passed the currently adhered-to legislation
limiting research to embryonic stem cell lines established only before 2001. In 2006, during
his second term as president, George W. Bush signed into law the Stem Cell Therapeutic
Research Act of 2005, which restricted funding for adult stem cell therapies and treatments
7

but not embryonic stem cell research. President Barack Obama in 2009 passed an executive
order that finally gave federal funding to the study of the established embryonic stem cell
lines.5-7
The abilities of embryonic stem cells (ESCs)—totipotency and continuous and rapid
regeneration without differentiating into one of the germ layers—have proved both
advantageous and harmful. Because of the close relationship with tumors, scientists
realized that stem cells, if not transplanted into an adult correctly, could induce tumors and
lead to cancer.8 Additionally, they discovered that while ESCs are totipotent, their
predisposed differentiation potentials could be seen by an adult body’s cells as foreign,
therefore causing the body to reject the cells.3

Stem cell characteristics
Stem cells are unique because of their ability to differentiate into any number of
different cell-types, depending on the type of stem cell.3 They can be totipotent,
pluripotent, or multipotent, etc. (Table 1). Pluripotency of stem cells specifically means the
ability of the cell to differentiate into all 3 germ layers—ectoderm, endoderm, and
mesoderm.6,7
Stem cells self-renew rapidly, making them ideal for regenerating undamaged cells
with the correct genetic makeup in areas where cells have been greatly damaged.3
However, this ability has the great potential to cause not only tumor growth, but malignant
tumor growth.8 These two characteristics are crucial to stem cell medicine, therefore
scientists have been focusing on finding pluripotent or totipotent cells that can proliferate
like ESCs. Because of the limitations and safety risks of using embryonic cells in adult bodies,
8

the scientific community decided that using one’s own cells was the best way to reduce the
risk of immune responses to outside genetic information.
Table 1. States of potency within cells6,7
Potency

Definition
The ability to divide into and produce all
possible differentiated cells, including
extraembryonic tissues

Examples of cells

Pluripotent

The ability to divide into and produce all cells of
the three germ layers (endoderm, ectoderm,
mesoderm)

Embryonic stem cells
Induced pluripotent stem cells
Some adult stem cells

Multipotent

The ability to divide into and produce cells in a
closely related family of cells of multiple
lineages

Hematopoietic stem cells

Oligopotent

The ability to divide into and produce few cells
of limited types of cell lineages

Lymphoid stem cells
Myeloid stem cells

Unipotent

The ability to divide into and produce only one
cell type through self-renewal properties of
stem cells

Muscle stem cells

Totipotent

Spores
Zygotes

Alternative techniques
A technique called somatic cell nuclear transfer (SCNT) was developed in which ESC
nuclei were transferred into adult somatic cells whose own nuclei had been removed. The
experiment proved that the genetic information and tendencies of ESC and early embryonic
cells were retained in their nuclei, allowing the somatic cell to reprogram and form into a
blastocyst.9 As this technique to induce pluripotency still employed the use of embryonic
cells, however, scientists kept searching for other methods to obtain ESC characteristics in
normal adult somatic cells. Another technique that held promise but was quickly discarded
was the cellular hybridization of somatic cell fusion with an ESC, because of its use of ESCs,
something scientists did not want to rely on.9

9

The SCNT technique spawned an entirely different field of research, that of cloning,
which led to the eventual cloning of ‘Dolly’ the sheep. However, the cloning experiments
also demonstrated and helped confirm earlier theories that cells differentiated due to
epigenetic changes in the cells, and that reversing those epigenetic changes—usually by
affecting histone wrapping and through methylation and acetylation—could cause a cell to
dedifferentiate, or return to an undifferentiated state.10
Inducing Pluripotency: the 2006 experiment11
It was not until 2006, when Kazutoshi Takahashi and Shinya Yamanaka published
their seminal paper and proved the possibility of inducing pluripotency without narrowed in
on a set of transcriptional factors present in ESCs that could be inserted into somatic cells of
any stage—they used mouse embryonic fibroblasts and adult tail-tip fibroblasts—to induce
a pluripotent state. Their findings, which set the stage for stem cell research until today,
found 4 transcription factors—Oct3/4, Sox2, Klf4, and c-Myc, together known as “OSKM”—
that were necessary to create induced pluripotent stem cells (iPSCs).10-15
Using 24 candidate genes known to be particular to ESCs, Takahashi and Yamanaka
used retroviral transduction to insert those genes into the fibroblasts and systematically
eliminated factors until a set of 10 were left. From there, the researchers eliminated more
factors until only 4 were left. A series of experiments confirmed that these specific factors
were essential, that fewer factors did not improve the already low efficiency of inducing
pluripotency. The results, repeated with adult fibroblasts, confirmed that any cell type could
undergo this method and become an iPSC. When compared to mouse ESCs, their new
induced pluripotent stem cells were very similar in morphology and phenotype, which
10

proved that their method not only worked, but that their findings of the 4 transcription
factors were correct as well.11
Oct3/4, Sox2, Klf4, and c-Myc, while researched extensively before 2006, have all
been the subject of further study, this time to discover the mechanisms of inducing
pluripotency. Each factor has a specific role in maintaining pluripotency, making each factor
important. Working in an interdependent capacity, the factors go through an
autoregulatory feedback look that enables for the maintenance of the ESC pluripotent
state.12 However, studies have confirmed that optimal efficiency for inducing pluripotency is
obtained through different concentrations of the factors being expressed.13 This is due,
research has shown, to the different roles each factor plays in cells.

Oct3/4
Oct3/4 is a factor involved in the maintenance of the self-renewal of pluripotent
cells and works closely with Sox2 and NANOG, two other transcription factors associated
with ESCs.10,14-17 Oct3/4, otherwise known as Oct3, Oct4, or POU5F1, is primarily expressed
in germline cells and is specifically involved in the formation of the inner cell mass of
blastocysts. A tightly regulated factor, Oct3/4 is required in large amounts when inducing a
cell to the pluripotent state and has the capacity to induce pluripotency on its own, but at
low efficiency. Without Oct3/4, however, a cell will not become an iPSC.12-16

Sox2
Sox2, a close cofactor of Oct3/4, is a member of the Sox gene family that exists in
the epiblast of elongating blastocysts.16 While only a small amount of Sox2 is required for
the pluripotent state,13 and while it is even sometimes completely dispensable to
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reprogramming,15 its presence works with Oct3/4 to ensure the cell stays pluripotent. Sox2
may also be involved in differentiation at a later stage, as certain amounts of Sox2 in a cell
can lead to trophoblast formation.18

Klf4
Klf4, a Kruppel-like zinc finger transcription factor, is involved in cell growth
regulation and differentiation. Klf4 is directly connected to tumor suppressor protein p53,
which is also involved in regulating the cell cycle. Like Sox2, only small amounts of Klf4
contribute to increased efficiency of cell reprogramming. One of the main functions of Klf4
is to suppress p53—which would otherwise prevent NANOG from being activated—and
lead to differentiation.14-16,18

c-Myc
The last of the factors, c-Myc, is perhaps the most dispensable. This basic helix-loophelix leucine zipper transcription factor has roles in cell growth, differentiation, and
proliferation. It can block differentiation or block proliferation, depending on the cell type
and depending on other factors around it. By far the gene with the most binding sites, cMyc works with the LIF (leukemia inhibitory factor) signaling pathway that helps maintain
pluripotency. When Klf4 activates p21, a target for p53, c-Myc can sometimes step in and
silence p21, therefore keeping the cell in a proliferating state. While not entirely required,
large quantities of c-Myc prevent iPSCs from apoptosis.14-16,18
While other factors have since been found that can induce pluripotency, OSKM are
still considered the main and most efficient transcription factors for inducing pluripotency

12

in a cell. These factors also transcend organisms—they are found in murine embryonic stem
cells as well as human embryonic stem cells (hESCs).
Inducing Pluripotency: the 2007 human experiment19
The ability to induce pluripotency in human somatic cells was proved in 2007 by
Takahashi and Yamanaka, just a year after their groundbreaking discovery that
reprogramming could be induced in mice.11 The two scientists reproduced their 2006
experiment and proved that human iPSCs could be formed from the transduction of OSKM
into human fibroblasts.19 Similar to mouse iPSCs, human iPSCs were morphologically and
phenotypically similar to hESCs. Some other genes were also found to be in both human and
murine stem cells (Fig. 1A,B), solidifying the theory that stem cells of any organism are
similar in genotype. A major difference between human iPSCs and murine iPSCs can be
found in the expression of these genes, however. The expression of certain genes in human
iPSCs mirrors those expressed in hESCs, while the expression of genes in murine iPSCs
differs slightly from mouse ESCs—some factors are less expressed in the iPSCs than in the
ESCs, and some genes, while known to be present in ESCs, are not expressed at all in iPSCs
(Fig. 1A), for example the gene ECAT1, the only gene not expressed to some extent in iPSMEF4-7. This difference in expression could account for the slight differences observed in
iPSCs.
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Visit
http://www.sciencedirect.com/science/article/pii/S00
92867406009767, Figure 3A
and
http://www.cell.com/fulltext/S00928674%2807%2901471-7, Figure 2A,
for access to Figure 1 A and B, respectively.

Figure 1. Gene expression of hES cell-marker genes. Comparison of genes tested for and
expressed in both mice and humans. A RT-PCR analysis of ES marker genes in mouse iPS
11
cells, ES cells, and MEFs. B RT-PCR analysis of ES cell-marker genes in human iPS cells,
19
ES cells from cell line H9, human embryonic carcinoma cell line NTERA-2, and HDFs.
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Difficulties with iPSCs
While induced pluripotent stem cells are very similar to ESCs, it has been found that
iPSCs still carry traces of their original cell types and are therefore more likely to
differentiate into certain cell types instead of being able to differentiate into any cell type.
Supporting this finding is the realization that the genes in ESCs and iPSCs differ in gene
expression.20 The stability of iPSCs has also come under question, as they seem genetically
unstable.
Other difficulties include iPSC generation efficiency: the most common method by
far of retroviral transduction—used by Takahashi and Yamanaka in the initial
experiments11,19—involves using a viral vector to introduce OSKM into a somatic cell. The
properties of the virus could also induce mutagenesis in the cell and, combined with OSKM
and the new pluripotent properties of the cell, lead to oncogenesis.21 Using a retrovirus
poses dangers, however, because of the body’s innate immune response to a foreign
substance—the host cell of the virus, upon identifying the virus, would initiate the sequence
of events that includes activation of p53 and eventual cell death.22 Additionally, the
retroviral vectors integrate randomly into the host chromosome, leading to leaky
expression for each cell and making the cells hetereogeneous.9 The efficiency of retroviral
transduction for cellular reprogramming is low, leading to the search for other methods to
get OSKM into somatic cells.
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Proposal
The characteristics of embryonic stem cells as described previously make them the
ideal to strive towards in iPSC research. Therefore many studies have, to date, found
epigenetic differences that could explain the genomic imprinting in iPSCs that differentiates
them from ESCs. If genetic expression differs between the two, it can be assumed that there
are molecular differences as well. The challenge is to find methods to reduce these
differences, to make iPSCs more similar to ESCs. A method proposed in this study is adding
an ESC-associated protein, which would theoretically confer more ESC characteristics on
iPSCs, whether through the presence of more ESC pluripotency markers, or through a
greater similarity in gene expression and methylation mapping between iPSCs and ESCs.

ECAT1
One such ESC-associated protein, whose gene was studied in Takahashi and
Yamanaka’s 2006 experiment, is the relatively unknown ECAT1. Also known as ES CellAssociated Transcript 1 or c6orf221, ECAT1 belongs to the ECAT family, which describes any
factors characterizing pluripotency such as Oct3/4, Sox2, and its fellow ECAT protein, ecat4,
or NANOG.23,24
It is not known for sure whether each member of the ECAT family has the same roles
in stem cells. For example, the nonessential NANOG activates transcription of pluripotency
markers to increase reprogramming,3,18 maintains pluripotency for longer in cells with it
compared to cells without it and thus changing cell morphology17, and may even activate
cancer-pathways, which highlights the thin line between stem cells and tumor cells that
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poses a risk in stem cell medicine3. ECAT1 differs in one respect: the protein contains an
atypical KH domain, commonly seen in DPPA5, OOEP, and KDHC1 proteins, all of which are
absent in rodents25. The KH domain is present in nucleic acid-binding proteins and allows for
binding of RNA as well as RNA recognition26.
Although ECAT1 is present in embryonic stem cells and oocytes, it was not found to
be expressed in initial reprogramming efforts in murine cells (Fig 1A).6 When
reprogramming was attempted with human somatic cells, the presence of ECAT1 was not
tested and confirmed. Since the study only tested the possibility of inducing pluripotency
using OSKM, and given ECAT1’s fellow factor NANOG’s role in maintaining pluripotency, it
could be assumed that ECAT1’s role—and presence—in inducing pluripotency in human
cells has yet to be extensively discussed, especially as so little is known about ECAT1.

Proposed Experiments
With research focusing on ways to replicate ESC characteristics when inducing
pluripotency in somatic cells, this could provide an opportunity to observe ECAT1 in more
depth by testing its effects on inducing pluripotency. This study therefore aims to look at
the effects of ECAT1 through the entire iPSC process, from reprogramming to
differentiation, in three stages:
1) ECAT1 will be used with the OSKM factors to induce
pluripotency in adult human fibroblasts using retroviral
transduction of polycistronic vectors.
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2) The newly-formed hiPSCs will be compared against hESCs for
any changes suggesting increased similarities between hiPSCs
and hESCs.
3) The differentiating ability of the new hiPSCs will be tested by
differentiating them into spinal motor neurons and analyzed for
functionality and similarities to existing motor neurons.
Using tried and true methods of previous studies researching iPSCs, this proposal
offers a chance to study a relatively unknown factor—ECAT1—and also discover more about
the differences between hiPSCs and hESCs.
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Materials & Methods
Stage 1: Retroviral transduction-based reprogramming
Because of its popular use in stem cell research, retroviral transduction will be used
as the method to induce pluripotency in adult human fibroblasts. Retroviral transduction
was first used in the seminal 2006 and 2007 papers that confirmed the possibility of
creating iPSCs (both murine and human). The efficiency of inducing pluripotency (Table 2)
using retroviruses, which, along with lentiviruses, are known as integrating viruses, is
relatively low27. However, non-integrating vector viral transduction—using adnoviruses and
RNA viruses like the Sendai virus28,29—as well as nonviral methods—direct protein
delivering,

non-integrating

episomal

vectors,

piggyBac

transposition30,

miRNAs,

nucleofection, mRNA31, minicircle vectors, artificial chromosome vectors32, and
nanoparticles33—which could lower the chances of inciting an immune response from
somatic cells during reprogramming9, yield lower reprogramming efficiency. Continuing
research has shown that efficiency increases with the supplementation of small chemical
compounds.
Table 2. Approximate reprogramming efficiencies of human fibroblasts27
Vector

Method

Approximate reprogramming efficiency in human
fibroblasts a

Virus

Retrovirus
Lentivirus
Adenovirus
Sendai virus

++++
+++
+
++++

DNA

Episomal plasmid
Transposon
Minicircle

+
++
+

RNA
Protein

RNA
+++
Cell transparent protein
+
a
+, <0.001%; ++, <0.01%; +++, <0.1%; ++++, >0.1%.
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In accordance with an experiment performed by Zhang et al34, human OSKM fusion
genes (hOSKM) with 2A sequences separating human cDNA sequences of each
reprogramming factor will be created (Figure 2A). This gene, along with another gene
sequence containing human cDNA for ECAT1 only, will be constructed into a vector,
pMIGR1, with high-expression MSCV (Murine Stem Cell Virus) promoter, which is especially
used in research with stem cells.35 A GFP marker will be cloned downstream of the factors,
after an IRES sequence, to enable factor tracking during the experiment. Retroviral 293T
cells will then be transfected with the vectors to create the retrovirus.34 One sample of

A
MSCV

5’LTR

IRES

E2A
hOCT3/
4

P2A
hSOX2

eGFP

3’LTR

T2A
hcMyc

hKLF4

B
5’LTR

MSCV

hECAT1

IRES

eGFP

3’LTR

Figure 2. pMIGR1 vector designs for retroviral transduction-based cell reprogramming.
MSCV: Murine Stem Cell Virus promoter. IRES: internal ribosomal entry site. A
Polycistronic vector with OSKM factors and inserted 2A sequences between35 B ECAT1containing retroviral vector. ECAT1’s close connections with Oct3/4 and Sox2 suggest
same promoter would work.
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retrovirus will have only the OKSM sequence vector, while another sample will have both
the OSKM sequence vector and the ECAT1 sequence vector.

Confirming pluripotency
To test the ability to reprogram, human dermal fibroblasts will be infected with the
retroviral T293 cells. Adult human fibroblasts have been extensively used in stem cell
studies37,38, making them the ideal candidates to test the effects of ECAT1. The cells will be
plated and grown in medium containing sodium butyrate, SB431542, and PD0325901,34
which have been shown to increas the efficiency of reprogramming somatic cells, and which
have supplemented the findings of researchers that certain chemicals and other growth
factors can increase reprogramming efficiency.9
A series of tests will confirm progress of reprogramming. To confirm transduction of
the factors into the fibroblasts, the cells will be studied for colony growth, GFP expression,
as well as cell morphology. The main success of this stage will be shown through formation
of cells, indicating that the retrovirus integrated into the cells instead of inciting an immune
response and cell death. The hiPSCs will be tested against human adult dermal fibroblasts as
well as a set of 6 hESC lines (Table 3), which have been used as comparisons to iPSC lines in
different experiments38. The multiple hESC lines should provide more information to be able
to compare the hiPSCs to the different variables within hESC lines themselves. RT-PCR
analysis of the cells should molecularly confirm presence and expression of the
reprogramming factors in the cells, and comparison of factor levels in hiPSCS and hESCs will
further confirm successful reprogramming.
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Table 3. Cells used in comparing pluripotency and other cell characteristics38
Cell Type
Variation
Sample
Somatic cell
HDF
Control
hiPS
OSKM
Control
hiPS
OSKM + ECAT1
Test

hESC

HuES-339
HuES-639
HuES-939
HuES-1339
HuES-3 hb9:GFP40
RUES141

Control

Stage 2: hiPSCs vs hESCs
The major component of this research proposal is studying the comparison between
the induced pluripotent stem cells and human embryonic stem cells, to see how similar the
two cell types are. Ideally, the newly-formed hiPSCs mirror hESCs exactly, in morphology,
cell marker expression, gene expression, and ability to differentiate into absolutely any of
over 200 different cell types12. Induced pluripotent stem cells retain an ESC-like rounded
shape, especially in the late passages of the cell20,42 and can therefore be one of the first
indications of pluripotency. In fact, the cell becomes is more stem cell-like during the late
passages than in the early passages, suggesting that the cell is constantly changing during
the reprogramming.20 Therefore, rounded cell morphology in late passage hiPSCs should
indicate pluripotency of the reprogrammed cells. The major comparisons will be done in the
forms of two studies: a molecular study and a genomic study.

Molecular comparisons
The markers of pluripotency have been identified through certain hESC surface
markers as well as the increased presence of certain enzymes. Expression of alkaline
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phosphatase, using an alkaline phosphatase assay, will be found. Additionally,
immunostaining will be performed not only for the reprogramming factors transfected into
the cells—Oct3/4, Sox2, Klf4, c-Myc, and ECAT1—but also pluripotency factors such as
NANOG, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81, all of which are present in hESCs4. The
most common immunostaining analysis method used in stem cell research is flow
cytometry, however Western blotting will also be used to confirm expression of OSKM and
ECAT1. These tests will be performed on the human dermal fibroblasts as well as the hESC
lines, to create comparisons.

Genomic comparisons
While the analysis of cell surface markers and pluripotency factors in the newly
reprogrammed hiPSC cells with ECAT1 can help, a deeper analysis of the differences in
genome between the hiPSCs and hESCs can help gain a deeper understanding for ECAT1’s
effects on somatic cells and therefore a better understanding of its function in embryonic
stem cells. There are approximately 3,947 genes out of 17,620 that are significantly
different between all established hiPSC and hESC lines20, making it the goal of this study to
see if that difference can be decreased with the presence of ECAT1.
To each cell sample, a genome-scale bisulfate sequencing, set of microarray assays,
and high-throughput transcript counting differentiation assay that made use of marker
genes in embryoid bodies.42
The bisulfate sequencing will map each DNA methylation site, allowing for the
comparisons of number and location of CpG dinucleotides across all cell samples. This is
important because reprogramming cells to pluripotency has been shown to be
23

accompanied by hypomethylation and changes to primarily pluripotency-related promoters
that are typical for ESCs.43,44 Focus on genes such as DNA methyltransferase DNMT3B,
antioxidant CAT, developmental regulator PAX6, and macrophage/granulocyte surface
marker CD14 should give better ideas of changes, as well.
The microarrays performed on each sample (Table 3) should give expression of
genes that can then be compared with each other and hopefully reveal fewer differences in
gene expression. The differentiation assay would look at RNA expression of genes
specifically associated with stem cells—those having to do with pluripotency,
differentiation, and cell state monitoring, etc. Specifically focusing on the reprogramming
pathway and genes associated with it in this assay will allow for a closer look at which
reprogramming-specific genes are affected during the course of the pathway.44 Statistical
analyses can help quantify patterns of behavior as well.

Stage 3: Differentiation
The final set of experiments testing the effects of ECAT1 on pluripotency will look at
differentiation of the hiPSCS and hESCs and compare the differentiated, newly-somatic cells
to their originally somatic cell counterparts. For this part of the experiment, the stem cells
will all be differentiated into spinal motor neurons, a type of cells that have proven difficult
to extract to study in vitro when diseased. hiPSCs and hESCS will be converted into
embryoid bodies, clusters of pluripotent stem cells that form in preparation for
differentiation using a typical embryoid body formation assay. These embryoid bodies can
then be made to differentiate into the neurons using specific growth factors and involving

24

the use of retinoic acid and the sonic hedgehog pathway in a common method of
differentiating pluripotent stem cells to neural cells.38

Confirming Differentiation
Confirmation of differentiation can be found through comparing morphologies of
the differentiated cells to existing motor neurons. Expression of TUJ1 and motor neuron
marker ISLET ½ (ISL) further confirms the exact identity of the newly differentiated cells.
Immunostaining for the presence of motor neuron-specific factors HB9, acetylcholine
synthesizer

ChAT, neural marker NCAM along with the neural precursor cells undoubtedly

generated from differentiation because of the low generation efficiency rate, and mRNA
encoding for markers like CHT1, can help confirm the accurate differentiation of the hiPSCs
and hESCs. Proof of proper motor neuron function can come with Ki67 immunostaining to
measure cycling rate of activity, as well as a Ca2+ assay that rigorously enhanced the
activities of the neuron during spontaneous activity as well as forced depolarization of the
membrane to open the gated Ca2+ channels. Immunostaining for ISL would confirm the
positive identity of the cells as spinal motor neurons.38 Electrophysiologial recordings of
cells made under standard and stressful conditions could help when comparing their activity
to existing spinal motor neurons, to look for similar data.
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Predicted Results
The ideal results for the three stages of this research proposal’s study show ECAT1
having a positive effect on reprogramming, on maintaining pluripotency, and on
differentiation. Because of ECAT1’s role in hESCs as that of an RNA binder, and because of
its visible detection in the cells before being silenced, when the cell begins developing and
differentiating, it can be assumed that ECAT1 helps maintain pluripotency. The presence of
ECAT1 should, if not actively change something in a reprogramming cell, at least influence
the unwinding of parts of DNA containing more pluripotency genes. ECAT1’s tendency to
bind nucleic acids would come in handy here, as it could manipulate the genome

Stage 1: Pluripotency
With or without ECAT1, the presence of the OSKM factors, coupled with the
chemicals sodium butyrate, SB431542, and PD0325901,34 which allow for more effective
reprogramming, should result in a yield of cells with pluripotent characters. Chief among
these is morphology. Embryonic stem cells are smooth and round-shaped, whereas somatic
cells tend to have more texture to their shapes. It would be easy to see a change in cell
shape. Positive identification of the expression of the reprogramming factors would confirm
the success of reprogramming. With ECAT1 present, it is the hope that more pluripotency
factors are influenced into becoming active, thereby raising the chances of an induced
pluripotent stem cell’s staying alive and healthy.
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Stage 2: Molecular Comparison
Embryonic stem cells have high levels of alkaline phosphatase to maintain
pluripotency, in addition to having high levels of NANOG, Oct3/4, Sox2, SSEA-3, SSEA-4,
TRA-1-60, TRA-1-80, and a host of other ESC markers. Immunostaining and then flow
cytometry and Western Blotting should show the presence of all these in not only the
OSKM-induced PSCs, but also the OSKM+ECAT-induced PSCs, as well as the established hESC
lines. Little to none of these markers should be detected in the adult human fibroblasts
used for reprogramming in the first place. As mentioned before, ECAT1’s presence in the
cell may induce a positive activation of other pluripotency genes kept tightly wrapped, and
so it is the hope that ECAT1 will be visible in analyses of immunostainings, and that
expression of pluripotency markers is higher.

Stage 2: Genomic Comparison
ECAT1’s role of manipulating nucleic acid binding sites may prove helpful in
unraveling the cell’s genome to allow expression of the previously-hidden pluripotency
genes. DNA methylation would be very different than before, and the approximately 4,000difference in gene expression between hiPSCs and hESCs would shrink. Because ECAT1 has
not previously been shown to be expressed naturally in cells more developed than
embryonic stem cells, this may have a dampening effect on the effects of ECAT1, which still
must be studied further for more information about its role in pluripotency. The counting
assay would allow a look at what reprogramming-specific genes are still inactivated in the
hiPSCs, which would pave the way for future studies looking into how to unlock those
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genes. Hopefully, again, ECAT1 has made a difference so that less genes need to be worked
on being activated.

Stage 3: Differentiation
Differentiation is a very common procedure, as the human body’s cells are more
likely to do that than to reprogram themselves. Hence, the differentiated cell yield should
be of a good size. The presence of ECAT1 may have more of an effect in helping sort the
genes to make the newly differentiated spinal motor neurons more efficient in their activity.
The series of rigorous testing is meant to see if the new cells can hold up to their more
established counterparts. Assuming that differentiation does not accidentally turn off any
crucial genes, the new spinal motor neurons should function in exactly the same ways.
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Significance & Conclusion
The field of stem cell research is growing because of interest in using stem cells to cure
diseases and heal injuries. Embryonic stem cells, because of the controversy surrounding
them—and subsequently the difficulties in acquiring samples of the existing aging cell
lines—can only be used in limited capacities. The development and study of induced
pluripotent stem cells has allowed the field to progress closer to therapeutical applications
of stem cells, yet there are still many challenges. iPSCs and ESCs are still remarkable
different in pluripotency character, and it has been shown on occasion that neither type of
stem cell can completely differentiate into a fully-functioning somatic cell. The efforts to
create stem cells that are identical to embryonic stem cells have proved and disproved a
number of methods, chemicals, factors, and conditions thought to improve pluripotency in
iPSCs. This proposal is one such research attempt to prove or disprove ECAT1’s role in
pluripotency. Since little is known about ECAT1, this research also attempts to characterize
ECAT1’s forced presence in iPSCs. With this study, it may just be that the key to unlocking all
of an iPSC’s pluripotent potential has been found. It is equally likely that ECAT1 has no
effect, or even a negative effect, on reprogramming and especially differentiation. The goal
of this research is to find out which of those effects is accurate, so that scientists can either
continue researching ECAT1, or know there is one less component to look at in the quest to
bring stem cell medicine to reality.
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